---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045995"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:42:24.204922+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601

## Summary
- ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.
- Net loss $44.0M ($0.42 per share) in Q3 2024 vs $46.7M ($0.57) in Q3 2023; adjusted net loss $29.4M.
- Cash and cash equivalents $274.3M as of Sep 30, 2024; expected runway into mid-2026.
- Discontinued ADCT-601 (AXL-targeting) due to unfavorable benefit-risk; prioritizing exatecan-based ADC platform.
- LOTIS-5 Phase 3 trial (ZYNLONTA+rituximab) full enrollment expected by year-end 2024; LOTIS-7 data update in Dec 2024.

## SEC filing metadata
- accession: 0001628280-24-045995
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828024045995/0001628280-24-045995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828024045995/adc-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045995
- JSON: https://secwatch.observer/filing/0001628280-24-045995.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045995.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.